Skip to main content
Ayu logoLink to Ayu
. 2012 Jul-Sep;33(3):418–422. doi: 10.4103/0974-8520.108858

Evaluation of subchronic genotoxic potential of Swarna Makshika Bhasma

Pavan B Savalgi 1,, Biswajyoti Patgiri 1, Jalaram H Thakkar 2, B Ravishankar 3, Varun B Gupta 4
PMCID: PMC3665102  PMID: 23723652

Abstract

Extremely diminutive published information is available on the mutagenic activity of Ayurvedic Bhasmas. Genotoxicity of few Bhasmas were reported on single maximum dose, but no reference is available on the sub-chronic level. Hence the present study was carried to generate and evaluate genotoxic potentials of Swarna Makshika Bhasma (mineral preparation) administered at therapeutic dose for 14 days. Chromosomal aberrations and abnormal sperm assay parameters were taken in this study. Cyclophosphamide (CP) was taken as positive group and results were compared. The results revealed a lack of generation of structural deformity in above parameters by tested drugs compared to CP treated group. Observed data indicate that the Bhasmas tested were non-genotoxic under the experimental conditions.

Keywords: Abnormal sperm assay, chromosomal aberrations, cyclophosphamide, genotoxicity, Swarna Makshika Bhasma

Introduction

Ayurveda is known and carried forward as an ancient Indian heritage. It is a traditional medical system used by a majority of Indian population.[1] The drugs known as “Bhasmas” are well-known in the traditional Indian Ayurveda and these are chemically mixed oxides of one or more metals.[2] Their traditional preparation involves conversion of a pure metal into its oxide form following a typical procedure, available in the ancient literature of Ayurveda.[3] Recently, doubts have been raised about the safety of Ayurvedic preparations using Bhasma and concerns were expressed regarding the metal toxicity of traditional preparations containing Bhasmas. Ayurveda fraternity claims that these medicines, if properly prepared and administered are safe and therapeutic.[4] According to them toxicity can arise only from a metal in its free form, and that a Bhasma prepared according to the classical methods never contains a metal in free form. Despite these theories claiming Bhasmas are non-toxic, documented case reports of poisoning was noted.[5,6] Hence the current study of Swarna Makshika Bhasma (SMB) would serve as a database of baseline information for genotoxicity, since there is apparently no literature on this aspect of mineral preparations.

Materials and Methods

Test drugs

Three different samples of Swarna Makshika (SM) were collected from different mines across India. Bhasmas were prepared according to classical reference.[7] Coded as mentioned below:

  1. SMB prepared from samples collected from Khetri Mine, Rajasthan (SMBKR).

  2. SMB prepared from samples collected from Hatti Gold Mine, Karnataka (SMBHK).

  3. SMB prepared from Malharjkhand Mine, Madhya Pradesh (SMBMM).

Chemicals

Colchicine was obtained from Hi-media, Mumbai. Cyclophosphamide (CP) procured as Cyphos vial from Intas Pharmaceuticals, Mumbai. Potassium chloride, methanol, acetic acid, giemsa stains were obtained from Sissco Research Laboratory, Mumbai, India.

Study design

Animals

Adult Swiss albino mice (weighing 25 ± 5 g) procured from an institutional animal house attached to SSR College of Pharmacy, Silvasa, where the study was conducted. Animals were maintained with controlled temperature (23 ± 2°C), relative humidity of 50 ± 10% and 12 h light/dark photo-period. The animals were acclimatized for 7 days prior to the experiment and provided with standard mice feed and distilled water ad libitum. Study was carried out after obtaining approval from Institutional Animal Ethics Committee (IAEC/2011/01).

Animals were randomly divided into five groups (5 mice per group) after an acclimatization period. Group I served as positive control and challenged with CP single-dose of 25 mg/kg body weight intra-peritoneally 24 h prior to termination. Group II served as vehicle control. Vehicle was prepared in combination of honey and deionized water (with a ratio of 1:1.5) and administered in the dose of 0.5 ml/kg body weight as per CCRAS/NIN guidelines. Group III, IV, and V received SMBKR, SMBHK and SMBMM at therapeutic dose 4.5 mg/kg body weight respectively along with vehicle for 14 consecutive days and sacrificed on the 15th day. The doses of test drugs were calculated as per the reference of Paget and Barnes (1969).

Body weight

Animals were examined throughout the experimental period for signs of gross toxicity. Body weight was recorded initially and at the time of sacrificed on the 15th day.

Experimental procedure

Chromosomal aberration assay

Animals were injected colchicine intra-peritoneally at the dose of 4 mg/kg body weight, on the 15th day in order to arrest dividing cells in metaphase[8] and sacrificed by cervical dislocation, 90 min after the colchicine treatment. Bone marrow cells from both femurs were extracted, subjected to hypotonic shock treatment (KCl 0.075 M), for about 30 min, at room temperature and then centrifuged at 1000 rpm for 10 min. The cells were fixed 5 times using freshly prepared methanol-acetic acid (3:1). The cells were spread on clean glass slides that were dried on a hot plate at 40°C. One more drop of fixative was added on slides to see more reliable pictures of chromosomes and then the slides were air dried at room temperature and finally stained with a 5% dilution of Giemsa reagent in a phosphate buffer (pH 6.8) for 15 min. The chromosomes of 1000 cells in metaphase abnormalities were analysed with a ×100 oil immersion objective, using a Trinocular Research Carl Zeiss Microscope (Germany). Metaphases with chromosomes and chromatid breaks, gaps, rings, stickiness, centric fusion, and deletion were recorded.[9]

Sperm abnormality assay

The method of Wyrobek and Bruce[10] was used for investigating sperm morphology abnormality assay. The test preparations were administered for 14 days, to correlate the results with positive control group. On 15th day, the overnight fasted animals were sacrificed by cervical dislocation and dissected out. Both the cauda epididymus were removed and placed in a watch glass containing 1 ml phosphate buffered saline (pH 7.2). Then minced and teased carefully well with fine scissors and forceps to release the spermatozoa. After gentle pipetting, the suspension was separated from the tissue fragments and filtered through double layers of muslin cloth to remove the tissue debris. A drop of Eosin Y solution (10:1) was added to this suspension and kept for 30 min. Air dried smears were prepared on clean, grease-free glass slides and a uniform smear was made. About 1000 sperms per animal were examined at ×400 magnifications from each treatment and control groups for the presence of sperm morphological abnormalities.

Statistical analysis

Statistical methods were carried out only to assess change in body weight by applying paired t-test. Statistics were not applied in CA assay and sperm abnormality assay. Different kinds of morphological changes were observed in CAs and sperm abnormal aberrations.

Observations and Results

The effect of SMBs on body weight, chromosomal aberration and sperm abnormality assay are shown in Tables 1-3.

Table 1.

Effect of SMBs on body weight

graphic file with name Ayu-33-418-g001.jpg

Table 3.

Effect of SMBs on sperm abnormality assay

graphic file with name Ayu-33-418-g003.jpg

Discussion

In vivo CA assay is one of the most frequently used and sensitive tests for the detection of the genotoxic profiles of drugs. The test has been recommended for routine analysis and data obtained are considered highly relevant in human context.[11,12] In the present study a 14-day sub-chronic genotoxicity of SMBs prepared by different samples are evaluated by employing in vivo CA assay and abnormal sperm assay (ASA). Although the genotoxic profile of some of Bhasmas have been evaluated in various studies,[13] Till date no reports of sub-chronic genotoxicity studies on Bhasmas and SMB are available. With this view body weight of animals also recorded after 14 days of drug administration and compared with CP group [Table 1]. All treated groups exhibited significant gain in body weight in comparison to CP. Body weight loss is an indicator of marked tissue loss in the body protein degradation. Gain of body weight is indicating that test drugs are not bearing degenerative potentials.

Colchicine is effective in causing metaphase stasis in cell dividing matrix.[14] Thus used to arrest metaphase, when chromosome structure seen noticeably. It inhibits microtubule polymerization by binding to tubulin, one of the main constituents of microtubules. Availability of tubulin is essential to mitosis, and therefore, colchicine effectively functions as a “mitotic poison” or spindle poison. Hypotonic solution (KCl) causes the cells to swell and enhances eventual separation of the chromosomes to facilitate visual analysis. CP is an anticancer drug that is widely used in anti-neoplastic therapy as well as in the treatment of some non-malignant diseases like rheumatoid arthritis. It is also used as an immunosuppressive agent prior to organ transplantation.[15] In somatic cells, CP has been shown to produce gene mutations, chromosome aberrations, micronuclei and sister chromatid exchanges in a variety of cultured cells in the presence of metabolic activation as well as sister chromatid exchanges without metabolic activation. The compound also produced chromosome damage and micronuclei in rats, mice and Chinese hamster.[16] Its use as a positive control chemical in genotoxicity tests has been recommended.[17] It increased the number of chromosome aberrations in the given dose with relatively high frequencies of chromosome breaks, centric fusion compared with other types of chromosome abnormalities. Gap, ring formation as well as stickiness were also frequent in CP treated group [Figure 1a-f]. This may be because almost all mouse chromosomes are acrocentric. These types of chromosomes have the exceptional facility to merge with each other. Only structural aberrations were enumerated in all treated groups [Figure 1g-j] against CP treated group, with special emphasis on chromosome and chromatid gap, breaks and centric diffusions placed in Table 2.

Figure 1a.

Figure 1a

CP-chromosomal and chromatid break and gap

Figure 1f.

Figure 1f

CP-Translocation and ring

Figure 1g.

Figure 1g

Normal chromosomes

Figure 1j.

Figure 1j

Normal chromosomes – SMBMM

Table 2.

Effect of SMBs on chromosomal aberration

graphic file with name Ayu-33-418-g002.jpg

Figure 1b.

Figure 1b

CP-Deletion

Figure 1c.

Figure 1c

CP- Pulverization

Figure 1d.

Figure 1d

CP-ring

Figure 1e.

Figure 1e

CP-stickiness

Figure 1h.

Figure 1h

Normal chromosomes – SMBKR

Figure 1i.

Figure 1i

Normal chromosomes – SMBHK

Morphological abnormalities of sperms are described as two types as head and tail abnormalities. The head abnormality included amorphous shape, without hook, banana shaped and folded head. CP treated group observed maximum number of abnormalities in both head and tail as shown in Table 3. Amorphous shaped head, hook less head and coil-tailed abnormalities were more frequent than other abnormalities of head and tail of CP treated group [Figures 2a-d]. The test preparations observed negative results in sperm abnormality showing non-toxic to sperms [Figures 2e-h]. Wyrobek[18] reported that large reductions in sperm number or mortality or large increases in sperm with abnormal shapes are associated with reduced fertility.

Figure 2a.

Figure 2a

CP – Hook less head

Figure 2d.

Figure 2d

CP – Amorphous shaped head

Figure 2e.

Figure 2e

Vehicle Control treated

Figure 2h.

Figure 2h

SMB MM treated

Figure 2b.

Figure 2b

CP – Deletion

Figure 2c.

Figure 2c

CP – Banana shaped head

Figure 2f.

Figure 2f

SMB KR treated

Figure 2g.

Figure 2g

SMB HK treated

Conclusion

Present study revealed that SMB prepared from different samples were found to be safe after the administration for 14 days at the therapeutic doses. No abnormality was noticed in CA and sperm abnormal aberrations in all trial groups. Further, above findings provide new information that may be more imperative for the use of Bhasmas.

Acknowledgment

Authors acknowledge to Chairman/Principle, SSR College of Pharmacy for his kind permission for the experimental study. Authors are also indebted to Director, Prof. M.S. Baghel, I.P.G.T. and R.A., G.A.U., Jamnagar, for financial support for the project. The authors are thankful to Prof. P. K. Prajapati, Head, and Dr. Galib, Asst. Prof., Dept of R.S. and B.K., I.P.G.T. and R.A., G.A.U., Jamnagar, for their valuable help.

References

  • 1.Gogtay NJ, Bhatt HA, Dalvi SS, Kshirsagar NA. The use and safety of non-allopathic Indian medicines. Drug Saf. 2002;25:1005–19. doi: 10.2165/00002018-200225140-00003. [DOI] [PubMed] [Google Scholar]
  • 2.Wadekar MP, Rode CV, Bendale YN, Patil KR, Prabhune AA. Preparation and characterization of a copper based Indian traditional drug: Tamra bhasma. J Pharm Biomed Anal. 2005;39:951–5. doi: 10.1016/j.jpba.2005.06.015. [DOI] [PubMed] [Google Scholar]
  • 3.Kulkarni–Dudhgaonkar SB. Rasaratna Samuchyaya of Vagbhatta. Kolhapur, India: Shivaji University Publication; 1970. p. 158. [Google Scholar]
  • 4.Ernst E. Heavy metals in traditional Indian remedies. Eur J Clin Pharmacol. 2002;57:891–6. doi: 10.1007/s00228-001-0400-y. [DOI] [PubMed] [Google Scholar]
  • 5.Araujo J, Beelen AP, Lewis LD, Robinson GG, DeLaurier C, Carbajal M, et al. Centres for Disease Control and Prevention. Lead poisoning associated with use of Ayurvedic Medications – five states, 2000-2003. MMWR Morb Mortal Wkly Rep. 2004;53:582–4. [PMC free article] [PubMed] [Google Scholar]
  • 6.Buwa S, Patil S, Kulkarni PH, Kanase A. Hepatoprotective action of abhrak bhasma, an ayurvedic drug in albino rats against hepatitis induced by CCl4. Indian J Exp Biol. 2001;39:1022–7. [PubMed] [Google Scholar]
  • 7.Vagbhatta, Rasaratna Samucchaya. In: 3rd ed. verse 2/78-80. Kulkarni DA, editor. New Delhi: Meharchandra Laxshandas Publication; 1987. p. 28. [Google Scholar]
  • 8.Mueller GA, Gaulden ME, Drane W. The effects of varying concentrations of colchicine on the progression of grasshopper neuroblasts into metaphase. J Cell Biol. 1971;48:253–65. doi: 10.1083/jcb.48.2.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tjio JH, Whang J. Chromosome preparations of bone marrow cells without prior in vitro culture or in vivo colchicine administration. Stain Technol. 1962;37:17–20. doi: 10.3109/10520296209114563. [DOI] [PubMed] [Google Scholar]
  • 10.Wyrobek AJ, Bruce WR. The induction of sperm shape abnormalities in mice and humans. In: Hallender A, de Serres FJ, editors. Chemical Mutagens. Vol. 5. NewYork: Plenum Press; 1975. pp. 275–85. [Google Scholar]
  • 11.Anonymous. International commission for protection against environmental mutagen and carcinogens report of committee. Mutat Res. 1983;114:120–77. doi: 10.1016/0165-1110(83)90038-6. [DOI] [PubMed] [Google Scholar]
  • 12.World Health Organization. Environmental Health Criteria 51. Geneva: WHO; 1985. Guidelines to short-term tests for detecting mutagenic and carcinogenic chemicals; pp. 100–14. [Google Scholar]
  • 13.Vardhini NV, Sathya TN, Murthy PB. Assessment of genotoxic potential of herbo-mineral preparations – Bhasmas (Research communications) Curr Sci. 2010;99:1096–100. [Google Scholar]
  • 14.Fraser IEB. The use of colchicine and colcemid for metaphase stasis in the matrix cells of wool follicles. Aust J Biol Sci. 1962;16:211–17. [Google Scholar]
  • 15.Jackson MA, Stack HF, Waters MD. Genetic activity profiles of anticancer drugs. Mutat Res. 1996;355:171–208. doi: 10.1016/0027-5107(96)00028-0. [DOI] [PubMed] [Google Scholar]
  • 16.Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. Cyclophosphamide: Review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res. 1995;330:115–81. doi: 10.1016/0027-5107(95)00039-l. [DOI] [PubMed] [Google Scholar]
  • 17.Krishna G, Petrere J, Anderson J, Theiss J. Use of cyclophosphamide as a positive control in dominant lethal and micronucleus assays. Mutat Res. 1995;335:331–7. doi: 10.1016/0165-1161(95)00038-0. [DOI] [PubMed] [Google Scholar]
  • 18.Wyrobek AJ, Gordon LA, Burkhart JG, Francis MW, Kapp RW, Jr, Letz G. An evaluation of the mouse sperm morphology test and other sperm tests in non-human mammals: A report of the US Environmental Protection Agency Gene Toxicology Program. Mutat Res. 1983;115:1–72. doi: 10.1016/0165-1110(83)90014-3. [DOI] [PubMed] [Google Scholar]

Articles from Ayu are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES